HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
POLR1A
RNA polymerase I subunit A
Chromosome 2 Β· 2p11.2
NCBI Gene: 25885Ensembl: ENSG00000068654.18HGNC: HGNC:17264UniProt: O95602
133PubMed Papers
22Diseases
1Drugs
10Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
magnesium ion bindingchromatin bindingDNA-directed RNA polymerase activityprotein bindingChoanal atresia-deafness-cardiac defects-dysmorphism syndromeacrofacial dysostosis Cincinnati typeleukodystrophy, hypomyelinating, 27acrofacial dysostosis
✦AI Summary

POLR1A encodes the catalytic core subunit of RNA polymerase I (Pol I), responsible for transcribing ribosomal DNA to produce 47S precursor rRNA, which is processed into mature 28S, 18S, and 5.8S rRNAs 1. As the largest Pol I subunit, POLR1A forms the active catalytic center with POLR1B/RPA2, catalyzing nucleotide addition via two coordinated Mg²⁺ ions and possessing proofreading activity through interaction with POLR1H/RPA12 [UniProt]. During transcription, Pol I progresses through initiation, elongation, and termination stages, with high processivity and formation of characteristic 'Miller tree' structures in rDNA regions [UniProt]. POLR1A mutations cause ribosomopathies with tissue-specific manifestations, particularly affecting craniofacial development 23. Heterozygous variants cause acrofacial dysostosis and related anomalies through cell-autonomous apoptosis in neural crest cells and cardiac lineages due to impaired ribosome biogenesis 2. Biallelic POLR1A mutations cause leukodystrophy with progressive neurological deficits, aberrant rRNA processing, and endoplasmic reticulum stress 1. The craniofacial vulnerability reflects high Pol I expression in neural crest progenitors, which depend on elevated rRNA synthesis and become particularly sensitive to synthesis defects 3. Beyond development, POLR1A supports ferroptosis resistance in cancer via nucleolar-mitochondrial signaling involving TFAM-mediated mitophagy and iron homeostasis, offering therapeutic targets through Pol I inhibition 4.

Sources cited
1
POLR1A encodes catalytic subunit of RNA Pol I; homozygous variants cause leukodystrophy with aberrant rRNA processing and endoplasmic reticulum stress
PMID: 36917474
2
Heterozygous POLR1A variants cause phenotypic heterogeneity including craniofacial anomalies, neurodevelopmental abnormalities, and cardiac defects; variant-specific effects on rRNA synthesis and nucleolar morphology
PMID: 37075751
3
High Pol I expression in neural crest cells sustains elevated rRNA transcription; loss of Polr1a in neural crest causes cell-autonomous apoptosis via p53 accumulation leading to craniofacial anomalies
PMID: 35881792
4
POLR1A controls TFAM expression and regulates mitophagy and iron homeostasis to suppress ferroptosis in cancer; CX-5461 Pol I inhibitor synergizes with ferroptosis inducers
PMID: 40669210
5
POLR1A is component of RNA polymerase I involved in rRNA synthesis regulation by autophagy and MTORC1 signaling
PMID: 35993412
Disease Associationsβ“˜22
Choanal atresia-deafness-cardiac defects-dysmorphism syndromeOpen Targets
0.78Strong
acrofacial dysostosis Cincinnati typeOpen Targets
0.73Strong
leukodystrophy, hypomyelinating, 27Open Targets
0.40Moderate
acrofacial dysostosisOpen Targets
0.37Weak
MicrognathiaOpen Targets
0.37Weak
microtiaOpen Targets
0.37Weak
benign prostatic hyperplasiaOpen Targets
0.27Weak
neurodegenerative diseaseOpen Targets
0.23Weak
genetic disorderOpen Targets
0.19Weak
intellectual disability, autosomal dominant 9Open Targets
0.12Weak
multiple congenital anomalies/dysmorphic syndromeOpen Targets
0.12Weak
head and neck malignant neoplasiaOpen Targets
0.09Suggestive
age-related macular degenerationOpen Targets
0.08Suggestive
X-linked retinal dysplasiaOpen Targets
0.07Suggestive
choroidal dystrophy, central areolar, 1Open Targets
0.06Suggestive
Familial exudative vitreoretinopathyOpen Targets
0.06Suggestive
severe early-childhood-onset retinal dystrophyOpen Targets
0.06Suggestive
Stargardt diseaseOpen Targets
0.06Suggestive
reticular dystrophy of the retinal pigment epitheliumOpen Targets
0.06Suggestive
age related macular degeneration 2Open Targets
0.05Suggestive
Acrofacial dysostosis, Cincinnati typeUniProt
Leukodystrophy, hypomyelinating, 27UniProt
Pathogenic Variants10
NM_015425.6(POLR1A):c.2267_2288del (p.Ser756fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 756
NM_015425.6(POLR1A):c.2374dup (p.Tyr792fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 792
NM_015425.6(POLR1A):c.2164C>T (p.Arg722Ter)Likely pathogenic
Acrofacial dysostosis Cincinnati type
β˜…β˜†β˜†β˜†2025β†’ Residue 722
NM_015425.6(POLR1A):c.2357C>T (p.Thr786Ile)Pathogenic
Leukodystrophy, hypomyelinating, 27
β˜…β˜†β˜†β˜†2025β†’ Residue 786
NM_015425.6(POLR1A):c.928C>T (p.Arg310Cys)Likely pathogenic
POLR1A-related disorder
β˜…β˜†β˜†β˜†2024β†’ Residue 310
NM_015425.6(POLR1A):c.190del (p.Cys64fs)Likely pathogenic
Acrofacial dysostosis Cincinnati type
β˜…β˜†β˜†β˜†2022β†’ Residue 64
NM_015425.6(POLR1A):c.4685G>T (p.Cys1562Phe)Likely pathogenic
not provided|Acrofacial dysostosis Cincinnati type
β˜…β˜†β˜†β˜†2017β†’ Residue 1562
NM_015425.6(POLR1A):c.1777G>C (p.Glu593Gln)Pathogenic
Acrofacial dysostosis Cincinnati type
β˜†β˜†β˜†β˜†2015β†’ Residue 593
NM_015425.6(POLR1A):c.3649del (p.Gln1217fs)Pathogenic
Acrofacial dysostosis Cincinnati type
β˜†β˜†β˜†β˜†2015β†’ Residue 1217
NM_015425.6(POLR1A):c.2527C>T (p.Arg843Ter)Pathogenic
Acrofacial dysostosis Cincinnati type
β˜†β˜†β˜†β˜†β†’ Residue 843
View on ClinVar β†—
Drug Targets1
TAS-106Phase II
DNA-directed RNA polymerase III subunit RPC1 inhibitor
head and neck malignant neoplasia
Related Genes
POLR2KProtein interaction100%TAF1CProtein interaction100%TAF1AProtein interaction100%POLIProtein interaction100%NOP56Protein interaction100%RRN3Protein interaction100%
Tissue Expression6 tissues
Heart
100%
Bone Marrow
92%
Ovary
91%
Liver
87%
Lung
86%
Brain
84%
Gene Interaction Network
Click a node to explore
POLR1APOLR2KTAF1CTAF1APOLINOP56RRN3
PROTEIN STRUCTURE
Preparing viewer…
PDB7OB9 Β· 2.70 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.48Moderately Constrained
pLIβ“˜
0.91Intolerant
Observed/Expected LoF0.39 [0.32–0.48]
RankingsWhere POLR1A stands among ~20K protein-coding genes
  • #3,495of 20,598
    Most Researched133 Β· top quartile
  • #2,838of 5,498
    Most Pathogenic Variants10
  • #2,788of 17,882
    Most Constrained (LOEUF)0.48 Β· top quartile
Genes detectedPOLR1A
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
POLR1A variants underlie phenotypic heterogeneity in craniofacial, neural, and cardiac anomalies.
PMID: 37075751
Am J Hum Genet Β· 2023
1.00
2
POLR1A inhibits ferroptosis by regulating TFAM-mediated mitophagy and iron homeostasis.
PMID: 40669210
Redox Biol Β· 2025
0.90
3
Dynamic regulation and requirement for ribosomal RNA transcription during mammalian development.
PMID: 35881792
Proc Natl Acad Sci U S A Β· 2022
0.80
4
The plasma peptides of Alzheimer's disease.
PMID: 34182925
Clin Proteomics Β· 2021
0.70
5
Autophagy regulates rRNA synthesis.
PMID: 35993412
Nucleus Β· 2022
0.60